271 related articles for article (PubMed ID: 30773521)
21. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience].
Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
[TBL] [Abstract][Full Text] [Related]
22. [Light Chain Amyloidosis: an Update for Treatment].
Shen KN; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):910-4. PubMed ID: 26117060
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.
Shen KN; Zhang CL; Tian Z; Feng J; Wang YN; Sun J; Zhang L; Cao XX; Zhou DB; Li J
Amyloid; 2019 Jun; 26(2):66-73. PubMed ID: 31074308
[No Abstract] [Full Text] [Related]
24. Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.
Zhang CL; Qiu Y; Shen KN; Miao HL; Feng J; Cao XX; Zhang L; Jiang XY; Zhou DB; Li J
Leuk Res; 2019 Jun; 81():19-24. PubMed ID: 30981853
[TBL] [Abstract][Full Text] [Related]
25. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
26. Autologous Hematopoietic Cell Transplantation Versus Chemotherapy Alone for Immunoglobulin Light Chain Amyloidosis: A Retrospective Study.
Miyazaki K; Suzuki K
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):413-422.e5. PubMed ID: 31023593
[TBL] [Abstract][Full Text] [Related]
27. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
[TBL] [Abstract][Full Text] [Related]
28. A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee.
Fuchida SI; Ogura M; Ishida T; Hata H; Handa H; Katoh N; Nakaseko C; Sunami K; Katayama Y; Nobata H; Oshiro K; Iida S; Sekijima Y; Naiki H; Shimazaki C
Int J Hematol; 2023 Oct; 118(4):443-449. PubMed ID: 37515656
[TBL] [Abstract][Full Text] [Related]
29. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients.
Huang X; Ren G; Chen W; Guo J; Zhao L; Zeng C; Ge Y; Liu Z
Amyloid; 2021 Jun; 28(2):75-83. PubMed ID: 33084412
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Jimenez-Zepeda VH; Duggan P; Neri P; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e79-84. PubMed ID: 27101985
[TBL] [Abstract][Full Text] [Related]
31. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis.
Briasoulis A; Bampatsias D; Petropoulos I; Rempakos A; Patras R; Theodorakakou F; Makris N; Dimopoulos MA; Stamatelopoulos K; Kastritis E
Eur Heart J Cardiovasc Imaging; 2024 Apr; 25(5):698-707. PubMed ID: 38142437
[TBL] [Abstract][Full Text] [Related]
32. Validation of the Boston University staging system in AL amyloidosis.
Tomlinson R; Matigian N; Mollee P
Amyloid; 2019 Sep; 26(3):125-127. PubMed ID: 31145007
[No Abstract] [Full Text] [Related]
33. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
34. Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
Bézard M; Oghina S; Vitiello D; Kharoubi M; Kordeli E; Galat A; Zaroui A; Guendouz S; Gilles F; Shourick J; Hamon D; Audard V; Teiger E; Poullot E; Molinier-Frenkel V; Lemonnier F; Agbulut O; Le Bras F; Damy T
PLoS One; 2021; 16(9):e0257189. PubMed ID: 34525116
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
Lilleness B; Ruberg FL; Mussinelli R; Doros G; Sanchorawala V
Blood; 2019 Jan; 133(3):215-223. PubMed ID: 30333122
[TBL] [Abstract][Full Text] [Related]
36. Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis.
Lilleness B; Doros G; Ruberg FL; Sanchorawala V
Br J Haematol; 2020 Feb; 188(3):424-427. PubMed ID: 31515797
[TBL] [Abstract][Full Text] [Related]
37. Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.
Milani P; Dispenzieri A; Scott CG; Gertz MA; Perlini S; Mussinelli R; Lacy MQ; Buadi FK; Kumar S; Maurer MS; Merlini G; Hayman SR; Leung N; Dingli D; Klarich KW; Lust JA; Lin Y; Kapoor P; Go RS; Pellikka PA; Hwa YL; Zeldenrust SR; Kyle RA; Rajkumar SV; Grogan M
Circ Cardiovasc Imaging; 2018 May; 11(5):e006588. PubMed ID: 29752392
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
39. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
